Melissa Leichter Announces The Newly FDA Approved Subcutaneous Prophylactic Treatment for Hemophilia A or B
Melissa Leichter, Rare Disease Executive, Novo Nordisk, shared a proud announcement post on LinkedIn:
”Today marks an exciting step forward for the hemophilia community. The FDA has approved our new subcutaneous prophylactic treatment for patients aged 12 and older living with hemophilia A or B.
This approval builds on our earlier indication for people living with hemophilia with inhibitors and reflects our continued commitment to expanding access and reimagining care across the hemophilia landscape.
Behind this milestone is a team of passionate, driven individuals who work tirelessly to bring innovative solutions to life. I am incredibly proud to be part of this journey—one that’s focused on delivering better options and more control for people navigating life with hemophilia. Thank you to the entire team who has contributed to this great achievement. Your dedication makes a real difference.”
Melissa Leichter proudly shares news on FDA Approvement for Alhemo.
Latest news in the field of Hemophilia Management featured in Hemostasis Today.
-
Nov 10, 2025, 10:16Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
-
Nov 10, 2025, 10:15Laurent Bertoletti Invites You to the Joint INNOVTE and GITA Meeting on Hormones and Thrombosis
-
Nov 10, 2025, 10:15Christopher Cannon: DOAC Monotherapy Wins Again
-
Nov 10, 2025, 10:14Marieke Kruip on Sex differences in Outcomes of VKA Treatment in Patients with Mechanical Heart Valve
-
Nov 10, 2025, 10:14Ana Paula Lacombe: From Research to Bedside, Innovation in Stroke Care is Moving Fast!
-
Nov 10, 2025, 10:13Jan Sloves: Understanding Iliofemoral DVT – What You Can’t Afford to Miss
-
Nov 10, 2025, 10:12Mohamed Rawy Shares a Comprehensive Guide For Anticoagulation
-
Nov 10, 2025, 10:10Marc Carrier: Proud to Share the Results of the WAVe Study
-
Nov 10, 2025, 10:07Frederik Denorme – The New PI at the Laboratory of Cell Biology and Histology at University of Antwerp